DOW JONES22,327.48+690.70 3.19%
S&P 5002,626.65+85.18 3.35%
NASDAQ7,774.15+271.77 3.62%

Barclays Initiates Coverage On Karyopharm Therapeutics with Overweight Rating, Announces $30 Price Target

Barclays analyst Peter Lawson initiates coverage on Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight rating and a $30 price target.

Benzinga · 03/04/2020 10:21

Barclays analyst Peter Lawson initiates coverage on Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight rating and a $30 price target.